Kynexis

Kynexis is a biotechnology startup founded in 2023, focused on advancing precision therapeutics for brain diseases. The company's lead candidate, KYN-5356, is a first-in-class small molecule targeting KAT-II, a key enzyme in the kynurenine pathway, for the treatment of cognitive impairment associated with schizophrenia (CIAS). Kynexis adopts a biomarker-based approach to identify and stratify patients based on the underlying causal human biology of the disease. Their last investment, a €57.00M Series A investment, took place on 07 November 2023 and was led by notable investors including Sunstone Capital, Forbion, and Ysios Capital. The company is positioned at the forefront of advancing the first potential precision medicine for CIAS, addressing a critical unmet need in the healthcare industry.